BioMarin Inks $4.8B Amicus Buy As Patent Litigation Resolved
BioMarin Pharmaceutical Inc. has agreed to acquire Amicus Therapeutics for $4.8 billion, in a deal bolstered by Amicus' settlement of patent litigation that secures U.S. exclusivity for its Galafold drug until...To view the full article, register now.
Already a subscriber? Click here to view full article